|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
88,430,000 |
Market
Cap: |
169.79(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.56 - $8.26 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Caribou Biosciences is a clinical-stage genome-editing biopharmaceutical company focused on developing transformative Clustered Regularly Interspaced Short Palindromic Repeats therapies for patients with devastating diseases. Co.'s primary product candidate, CB-010, is a clinical-stage allogeneic anti-CD19 chimeric antigen receptor (CAR)-T cell therapy with programmed cell death protein 1 removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. CB-012 is Co.'s allogeneic armored CAR-T cell product candidate targeting CD371, which is in preclinical development for the treatment of relapsed or refractory acute myeloid leukemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
15,627 |
Total Sell Value |
$0 |
$0 |
$0 |
$143,464 |
Total People Sold |
0 |
0 |
0 |
2 |
Total Sell Transactions |
0 |
0 |
0 |
2 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Obyrne Jason |
Chief Financial Officer |
|
2024-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
33,000 |
59,224 |
|
- |
|
Khan Ruhi Ahmad |
Chief Business Officer |
|
2024-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
33,000 |
33,000 |
|
- |
|
Mcclung Barbara G |
Chief Legal Officer |
|
2024-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
33,000 |
409,566 |
|
- |
|
Kanner Steven |
Chief Scientific Officer |
|
2024-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
33,000 |
387,037 |
|
- |
|
Haurwitz Rachel E. |
President and CEO |
|
2024-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
118,700 |
158,700 |
|
- |
|
Kanner Steven |
Chief Scientific Officer |
|
2024-02-06 |
4 |
OE |
$2.69 |
$82,252 |
D/D |
30,577 |
354,037 |
|
- |
|
Haurwitz Rachel E. |
President and CEO |
|
2023-06-08 |
4 |
OE |
$2.96 |
$29,600 |
D/D |
10,000 |
40,000 |
|
- |
|
Haurwitz Rachel E. |
President and CEO |
|
2023-03-20 |
4 |
OE |
$2.96 |
$29,600 |
D/D |
10,000 |
30,000 |
|
- |
|
Rizvi Syed Ali-Aamir |
Chief Medical Officer |
|
2023-01-19 |
4 |
S |
$6.31 |
$35,506 |
D/D |
(5,627) |
59,373 |
|
31% |
|
Kanner Steven |
Chief Scientific Officer |
|
2022-12-02 |
4 |
OE |
$2.69 |
$57,569 |
D/D |
21,401 |
323,460 |
|
- |
|
Fischesser Ryan |
VP of Finance and Controller |
|
2022-10-06 |
4 |
OE |
$2.69 |
$19,305 |
D/D |
5,678 |
116,044 |
|
- |
|
Fischesser Ryan |
VP of Finance and Controller |
|
2022-10-06 |
4 |
S |
$10.80 |
$107,958 |
D/D |
(10,000) |
110,366 |
|
37% |
|
Mcclung Barbara G |
Chief Legal Officer |
|
2022-09-15 |
4 |
OE |
$2.69 |
$74,231 |
D/D |
27,595 |
376,566 |
|
- |
|
Kanner Steven |
Chief Scientific Officer |
|
2022-08-25 |
4 |
AS |
$11.22 |
$485,221 |
D/D |
(43,248) |
302,059 |
|
-39% |
|
Kanner Steven |
Chief Scientific Officer |
|
2022-08-25 |
4 |
OE |
$2.69 |
$116,337 |
D/D |
43,248 |
345,307 |
|
- |
|
Fischesser Ryan |
VP of Finance and Controller |
|
2022-08-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,848 |
120,366 |
|
- |
|
Kanner Steven |
Chief Scientific Officer |
|
2022-05-13 |
4 |
OE |
$1.81 |
$140,081 |
D/D |
74,420 |
302,059 |
|
- |
|
Haurwitz Rachel E. |
President and CEO |
|
2022-05-09 |
4 |
OE |
$2.96 |
$29,600 |
D/D |
10,000 |
20,000 |
|
- |
|
Fischesser Ryan |
VP of Finance and Controller |
|
2022-03-15 |
4 |
OE |
$2.69 |
$7,733 |
D/D |
2,274 |
113,244 |
|
- |
|
Kanner Steven |
Chief Scientific Officer |
|
2022-03-04 |
4 |
OE |
$2.69 |
$31,036 |
D/D |
10,720 |
227,639 |
|
- |
|
Obyrne Jason |
Chief Financial Officer |
|
2022-02-08 |
4 |
OE |
$4.11 |
$100,021 |
D/D |
24,336 |
24,336 |
|
- |
|
Haurwitz Rachel E. |
President and CEO |
|
2022-01-26 |
4/A |
OE |
$2.96 |
$29,600 |
D/D |
10,000 |
10,000 |
|
- |
|
Haurwitz Rachel E. |
President and CEO |
|
2022-01-26 |
4 |
OE |
$2.96 |
$29,600 |
D/D |
10,000 |
3,359,395 |
|
- |
|
Rizvi Syed Ali-Aamir |
Chief Medical Officer |
|
2022-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
65,000 |
|
- |
|
Rizvi Syed Ali-Aamir |
Chief Medical OfficerOfficer |
|
2022-01-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,000 |
|
- |
|
32 Records found
|
|
Page 1 of 2 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|